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1122A-167 Improved  Surv iva l  and Reduced Bleed ing  With Low- 
Molecular-Weight Heparin Across All Acute Coronary 
Syndrome Subsets: Findings From the Global Registry 
of Acute Coronary Events 
Warner Klein, Wilfded Kraxner, Ronald Hddls, Ph. Gabriel Stag, Andrzej Budaj, Dietrich 
Gulba, Frans Van de Weft, Immad Sediq, Kami White, Keith A. A. Fox, for the GRACE 
Investigators, Medizinische UniversitMsklinik, Graz, Austria, The Royal Infirmary of 
Edinburgh, Edinburgh, United Kingdom. 
Background: No systematic study has taken place in the "real-world' setting to compare 
the safety and efficacy of unfractionatad heparin (UFH) and low-molecular-weight hep- 
adn (LMWH) in ACS. 
Aim: To identify patterns of use of UFH and LMWH and to compare their efficacy and 
safety in a wide spectrum of ACS pts enrolled in GRACE. 
Methods: Use of LMWH and UFH was analysed in 12,665 ACS pts according to patient 
history, concomitant reatment and invasive procedures in US and non-US sites. Dura- 
tion of use in hospitals +/- PCI facilities was investigated, and efficacy and safety out- 
comes were analysed. 
Results: Younger pts (<60 yrs), smokers, those receiving antiplatalets, thrombolytics, ~- 
blockers, ACE inhibitors, pts admitted to hospitals with PCI facilities, and pts undergoing 
invasive procedures were more likely to receive UFH than LMWH. LMWH was used less 
often in US than non-US sites. Duration of treatment with LMWH was >24 h in >90% of 
pts, and was significantly longer in sites without PCI facilities. Patients receiving LMWH 
had significantly lower rates of hospital mortality (p=.005), bleeding (p<.000f) and 
strokes (p=.047). These differences remained significant after adjustment for ccvari- 
ables. Mortality rate with LMWH was reduced by 29% (p=.0113) and bleeding by 45% 
(p=.0003). Similar results were observed in STEMI and NSTEMI/UA subgroups. 
Subgroup Outcomes Adjusted OR P-value 
(95%CI) 
Overall ACS Death 0.710 (0.544-0.925) 0.0113 
Major bleeding 0.554 (0.402-0.763) 0.0003 
STEMI Death 0.612 (0.392-0.955) 0.0305 
Major bleeding 0.548 (0.299-1.004) 0.0514 
NSTEMI Death 0.732 (0.523-1.025) 0.0695 
Major bleeding 0.592 (0.399-0.880) 0.0095 
Conclualona: UFH tends to be used more frequently than LMWH, but hospital outcomes 
were significantly better with LMWH after adjusting for covariables. 
1122A-168 Qual i ty  o f  L i fe Outcomes  in Acute Coronary 
Syndromes: Reasons Why Non-ST Elevation Patients 
Do Worse 
Padma Kaul. Yufing Fu, David Knight, Nancy Clapp-Channing, Wanda Sutherland, 
Christopher Granger, Daniel Mark, Duke C/inica/ Research Institute, Durham, North 
Carolina, University of Alberta, Edmonton, A/berta, Canada. 
Little is currently known about how quality of life (QOL) varies among subgroups of acute 
coronary syndrome (ACS) pts and how it is affected by therapeutic strategies. We pro- 
spectivaly examined QOL outcomes and procedure use at baseline and I year among a 
random US cohort of 1222 non-ST elevation (511 MI) and 562 ST-elevation (elev) MI pts 
in GUSTO-lib. Non-ST-elev MI pts were older and women were more likely to present 
with unstable angina (Table). Among 1-year survivors, ST-elev MI pts had the highest 
QOL both at baseline and at 1-year (unadjusted). In a multivadable regression model, 
higher baseline QOL and in-hospital revascularization status were significantly associ- 
ated with higher QOL status at 1-year. However, ACS subgroup, i.e., ST-elev vs. non-ST- 
elev, was not a significant independent predictor of QOL. 
Conclusion: Our study shows that the differential impact of the clinical spectrum of ACS, 
as described by unstable angina, non-ST-alev MI and ST-elev MI, on clinicat end-points 
extends to QOL outcomes. However, the significantly lower functional status observed 
among non-ST-elev patients is explained by differences in demography, comorbidity, 
QOL at baseline, and the differential use of revascularization in these pt subgroups. 
Selected Outcomes & Procedure Rates Among ACS Subgroups 
Non-ST Elevation UA Non-ST Elevation MI ST Elevation MI 
Baseline 1-yr Baseline 1-yr Baseline 1 -yr 
Age (yrs) + 63 64 62 
Female % 39 31 29 
QOL 
Duke Activity 18 19 24 23 31 27 
Status Index + 
Current health 70 75 75 80 80 80 
perception + 
Vitality + 42 50 50 58 67 58 
Mental health + 80 80 87 87 87 87 
PROCEDURES % 
Cath 80 82 87 88 84 87 
PCI 29 34 41 46 50 53 
CABG 16 21 23 33 14 22 
+ = Median values 
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1122A-169 Pat ients  With Ins ign i f i cant  T ropon ln  T Elevations Are 
More Likely to Have Coronary Artery Disease 
Diagnosed 
Charles A. Hendkson, David E. Bush, Eric E. Howell, Glenn Meininger, J. Shawn Miles, 
Andrew Bushnell, Nisha Chandre-Strobos, Johns Hopkins Medical Institutions, 
Baltimore, Maryland. 
Background: Elevation of troponin T in patients presenting to the Emergency Depart- 
ment with chest pain portends poor outcomes. However, marginal elevations of troponin 
T are often considered to be insignificant, and seldom factor into clinical decision-mak- 
ing. 
Methods: To assess the clinical relevance of marginal troponin T elevations, 487 con- 
secutive patients presenting to a city teaching hospital Emergency Department with 
ongoing chest pain were evaluated. Because of the known effects of renal insufficiency 
on troponin T levels, patients with creatinine > 1.9 mg/dL were excluded, as were 
patients who ruled in for myocardial infarction (troponin T > 0.09 ng/ml). 
Results: A total of 405 patients were enrolled in this study, which encompasses a four- 
month clinical outcomes assessment. 51 patients had "insignificant' marginal troponin T 
elevations (0.02-0.09 ng/ml), and 354 had normal levels (<=0.01 ng/ml). The patients 
with marginal elevations, as compared to those with normal levels, were older (64.9 v. 
56.2 years p=0.002), but less likely to smoke (32.0 v. 47.0% p=0.047) or have a family 
history of coronary artery disease (CAD) (26.7% v. 41.5% p=0.037). Rates of diabetes, 
hypertension, hypercholesterolemia, and prior history of CAD were similar between the 
two groups. Of the marginal troponin T elevation group (n=51), 49.0% of patients were 
referred for additional cardiac testing, and 36.0% of these patients had a positive test 
(positive stress test with or without imaging, or flow-limiting disease on cardiac angiogra- 
phy). On the other hand, in the group with normal troponin T (n=354), 56.7% of patients 
were referred for additional cardiac testing (p=NS), however, only 16.9% of those tested 
were positive (p=0.023). 
Conclusions: Marginal elevations of troponin T in patients presenting to the Emergency 
Department with chest pain identities a group of patients more likely to have ischemia 
diagnosed in hospital. Ongoing follow up for 4 months will define whether such patients 
with marginal elevations of troponin T are in fact at greater risk for adverse clinical out- 
comes and thus may warrant earlier aggressive therapy and intervention. 
1122A-170 Adherence  With Trad i t iona l  Med icat ion  and 
Complementary and Alternative Medicine Use Six 
Months After Hospital Discharge in Patients With Acute 
Coronary  Syndromes 
Eva M. Kline-Rooers. Prasanth Lingam, Sumit Sharma, Sara Warber, Christopher R. 
McBurney, Yasser Almanaseer, Kim A. Eagle, University of Michigan Health Systems, 
Ann Arbor, Michigan. 
Background: Complementary and Alternative Medicine (CAM) use is gaining popularity 
in U.S. patients with Acute Coronary Syndromes. The effects of CAM use related to 
adherence with evidence-based medicine (beta blockers (BB), aspirin (ASA), engiotansin 
converting enzyme (ACE) inhibitore, and lipid-lowering agents (LL)) are poorly described. 
In this pilot study, we determined the prevalence of CAM use in patients with Acute Coro- 
nary Syndrome, and its relation to use of evidence based medicine. 
Methods: 145 patients admitted to the University of Michigan Health Systems with a dis- 
charge diagnosis of Acute Coronary Syndrome (St segment elevation MI, non-ST seg- 
ment elevation MI or unstable angina) were identified from August 2000 to January 2001. 
Clinical data including medications at discharge were obtained retrospectively from med- 
ical records. Six months after discharge, patients were interviewed using a standardized 
questionnaire to determine CAM use and current prescription medicines. Adherence was 
measured by the percentage of patients, at 6 months, who were still using medications 
prescribed at discharge. 
Results: Overall 6 month adherence to evidence based therapies was between 70 and 
95% and was similar in CAM and Non-CAM subsets 
Drug CAM Non-CAM p-value 
(n=107) (n=38) 
ASA* 95.2 94.6 NS 
B.B. 84.6 77.1 NS 
ACE 71.2 65.5 NS 
L.L. 81.0 80.6 NS 
(*) Includes anti-platelet and/or anti-coagulant drugs 
Conclusion: While CAM use is common after discharge from Acute Coronary Syn- 
drome, this pilot study does not suggest that CAM use significantly impacts subsequent 
adherence to evidence-based medicine. 
